CHMP Knocks Back Teva On Cabazitaxel Hybrid

 
• By David Wallace
  
Hybrid
Teva’s Hybrid Application For Cabazitaxel Did Not Satisfy The CHMP • Source: Shutterstock

More from Regulation

More from Policy & Regulation